Claude Nicaise - Mar 12, 2025 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
Director
Signature
/s/ Cristin Rothfuss, as Attorney-in-Fact for Claude Nicaise
Stock symbol
SRPT
Transactions as of
Mar 12, 2025
Transactions value $
-$2,799
Form type
4
Date filed
3/13/2025, 08:00 PM
Previous filing
Mar 11, 2025
Next filing
May 27, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Options Exercise $245K +9.75K +47.41% $25.18 30.3K Mar 12, 2025 Direct
transaction SRPT Common Stock Sale -$248K -2.49K -8.22% $99.64 27.8K Mar 12, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRPT Stock Options (right to buy) Options Exercise $0 -9.75K -100% $0.00 0 Mar 12, 2025 Common Stock 9.75K $25.18 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were sold to cover the exercise price relating to the exercise of stock options to purchase shares, which are scheduled to expire in 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.64 and $99.87, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.